Nutex Health Inc. (NASDAQ:NUTX) Receives $243.33 Consensus Price Target from Analysts

Nutex Health Inc. (NASDAQ:NUTX) has received an average recommendation of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $243.3333.

Several equities research analysts recently issued reports on NUTX shares. Lake Street Capital assumed coverage on shares of Nutex Health in a research note on Tuesday, June 2nd. They set a “buy” rating and a $235.00 price target on the stock. Wall Street Zen cut shares of Nutex Health from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 20th. Zacks Research upgraded Nutex Health to a “hold” rating in a research note on Monday, June 29th. Weiss Ratings raised Nutex Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday. Finally, B. Riley Financial started coverage on Nutex Health in a research note on Friday, June 26th. They issued a “buy” rating and a $290.00 price target on the stock.

Nutex Health Trading Down 0.9%

NUTX opened at $147.43 on Friday. The firm’s 50 day moving average is $154.02 and its 200-day moving average is $129.58. Nutex Health has a 52-week low of $77.21 and a 52-week high of $204.00. The company has a quick ratio of 3.12, a current ratio of 3.14 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $1.01 billion, a P/E ratio of 11.39 and a beta of 0.21.

Nutex Health (NASDAQ:NUTX) last announced its earnings results on Thursday, April 30th. The company reported $6.52 earnings per share for the quarter, beating the consensus estimate of $3.99 by $2.53. The business had revenue of $216.49 million during the quarter, compared to the consensus estimate of $227.80 million. Nutex Health had a net margin of 10.95% and a return on equity of 23.50%. Analysts expect that Nutex Health will post 22.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Nutex Health

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its stake in shares of Nutex Health by 6,590.3% during the 4th quarter. Bank of America Corp DE now owns 2,074 shares of the company’s stock valued at $66,000 after buying an additional 2,043 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Nutex Health by 17.9% in the first quarter. Goldman Sachs Group Inc. now owns 18,119 shares of the company’s stock worth $852,000 after buying an additional 2,748 shares during the last quarter. Jane Street Group LLC acquired a new stake in Nutex Health in the first quarter valued at $522,000. JPMorgan Chase & Co. raised its holdings in Nutex Health by 41,430.0% in the second quarter. JPMorgan Chase & Co. now owns 8,306 shares of the company’s stock valued at $1,034,000 after acquiring an additional 8,286 shares in the last quarter. Finally, Legal & General Group Plc bought a new position in Nutex Health during the 2nd quarter valued at $454,000. 5.32% of the stock is currently owned by hedge funds and other institutional investors.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.